One of the cheapest stocks on the S&P. Amazon has challenged them as a drug store while competitors challenge them in the insurance side. If they raise their numbers and back that up with solid traffic projections, maybe a debt paydown, this stock could finally get the traction it deserves. They report Tuesday
One of the cheapest stocks on the S&P. Amazon has challenged them as a drug store while competitors challenge them in the insurance side. If they raise their numbers and back that up with solid traffic projections, maybe a debt paydown, this stock could finally get the traction it deserves. They report Tuesday
Known as a pharmacy, but the CEO has expanded it a lot. They bought insurer Aetna and are vertically integrated. Also own a pharmacy benefit manager, plus CVS operates 10,000 physical locations across the U.S., writing over a billion subscriptions annually. Currently, CVS is engaged in vaccine distribution. CVS trades at a cheap 10x PE and has a free cash flow yield of 13%. Well-managed. The market is starting to see this as more than just a drugstore chain. (Analysts’ price target is $85.17)
Known as a pharmacy, but the CEO has expanded it a lot. They bought insurer Aetna and are vertically integrated. Also own a pharmacy benefit manager, plus CVS operates 10,000 physical locations across the U.S., writing over a billion subscriptions annually. Currently, CVS is engaged in vaccine distribution. CVS trades at a cheap 10x PE and has a free cash flow yield of 13%. Well-managed. The market is starting to see this as more than just a drugstore chain. (Analysts’ price target is $85.17)
Stockchase Research Editor: Michael O'Reilly CVS, the 2nd largest pharmacy in the US, recently came under pressure with the announcement of Amazon stepping into the pharmacy space. However, now trading at 11x earnings, CVS is good value here -- especially after announcing they are hiring 15,000 staff in Q4 to likely become a mass vaccine distributor. Recent earnings of $1.66 per share beat expectations of $1.34. Management raised guidance of annual 2020 earnings to $7.35-$7.42 per share, above analyst calls for $7.23. It pays a great dividend, backed by a 33% payout ratio. We would buy this with a stop-loss at $57, looking to achieve over $82 -- over 21% potential. Yield 2.96% (Analysts’ price target is $82.43)
Stockchase Research Editor: Michael O'Reilly CVS, the 2nd largest pharmacy in the US, recently came under pressure with the announcement of Amazon stepping into the pharmacy space. However, now trading at 11x earnings, CVS is good value here -- especially after announcing they are hiring 15,000 staff in Q4 to likely become a mass vaccine distributor. Recent earnings of $1.66 per share beat expectations of $1.34. Management raised guidance of annual 2020 earnings to $7.35-$7.42 per share, above analyst calls for $7.23. It pays a great dividend, backed by a 33% payout ratio. We would buy this with a stop-loss at $57, looking to achieve over $82 -- over 21% potential. Yield 2.96% (Analysts’ price target is $82.43)
(A Top Pick Nov 21/19, Down 9%) He has exited this stock a while ago. Amazon entering the pharma space is negative for CVS. The split congress is a relief for the healthcare space. The pull back is probably exaggerated. A holistic company and a value trade. 3% dividend. Prefers to look elsewhere for more growth.
(A Top Pick Nov 21/19, Down 9%) He has exited this stock a while ago. Amazon entering the pharma space is negative for CVS. The split congress is a relief for the healthcare space. The pull back is probably exaggerated. A holistic company and a value trade. 3% dividend. Prefers to look elsewhere for more growth.
Struggling with high debt load. Healthcare space and insurance going into the US election, plus Supreme Court nomination, are creating uncertainty. Big boom in telehealth, and this bites into the local CVS option. It's going to be a very competitive business. Challenged. He'd go with UnitedHealth instead.
Struggling with high debt load. Healthcare space and insurance going into the US election, plus Supreme Court nomination, are creating uncertainty. Big boom in telehealth, and this bites into the local CVS option. It's going to be a very competitive business. Challenged. He'd go with UnitedHealth instead.
CVS Health Corp is a American stock, trading under the symbol CVS-N on the New York Stock Exchange (CVS). It is usually referred to as NYSE:CVS or CVS-N
In the last year, 21 stock analysts published opinions about CVS-N. 13 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is HOLD. Read the latest stock experts' ratings for CVS Health Corp.
CVS Health Corp was recommended as a Top Pick by Gordon Reid on 2021-02-18. Read the latest stock experts ratings for CVS Health Corp.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
21 stock analysts on Stockchase covered CVS Health Corp In the last year. It is a trending stock that is worth watching.
On 2021-03-04, CVS Health Corp (CVS-N) stock closed at a price of $69.17.